Get the Stockscreener App
25.35
14.33%
-5.00
Instil Bio Inc stock is traded at $25.35, with a volume of 746.92K.
It is down -14.33% in the last 24 hours and up +102.33% over the past month.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
See More
Previous Close:
$30.35
Open:
$28.49
24h Volume:
746.92K
Relative Volume:
4.24
Market Cap:
$170.30M
Revenue:
-
Net Income/Loss:
$-74.14M
P/E Ratio:
-2.2256
EPS:
-11.39
Net Cash Flow:
$-65.70M
1W Performance:
+23.69%
1M Performance:
+102.33%
6M Performance:
-3.38%
1Y Performance:
+135.51%
1-Day Range:
$23.47
$29.62
1-Week Range:
$22.46
$35.28
52-Week Range:
$9.62
$92.00
Instil Bio Inc Stock (TIL) Company Profile
Name
Instil Bio Inc
Sector
Industry
Phone
(972) 499-3350
Address
3963 MAPLE AVENUE, DALLAS
Compare TIL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TIL
Instil Bio Inc
|
25.96 | 161.44M | 0 | -74.14M | -65.70M | -11.39 |
|
ONC
Beone Medicines Ltd Adr
|
245.77 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.78 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.89 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.65 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Instil Bio Inc Stock (TIL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Perform |
| Apr-12-24 | Downgrade | Jefferies | Buy → Hold |
| Nov-01-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-01-22 | Downgrade | Truist | Buy → Hold |
| Aug-13-21 | Initiated | Robert W. Baird | Outperform |
| Apr-13-21 | Initiated | Cowen | Outperform |
| Apr-13-21 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-21 | Initiated | Truist | Buy |
View All
Instil Bio Inc Stock (TIL) Latest News
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - sharewise
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - sharewise
Instil Bio Elects Director and Ratifies Auditor - TipRanks
Instil Bio Advances Phase 2 Trial in China - TipRanks
(TIL) Proactive Strategies - news.stocktradersdaily.com
Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) - Seeking Alpha
H.C. Wainwright lifts Instil Bio stock target to $125 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Instil Bio stock target to $125 - Investing.com
Instil Bio (TIL) Receives Price Target Upgrade by HC Wainwright & Co. | TIL Stock News - GuruFocus
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following P - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst - GlobeNewswire
Instil Bio and ImmuneOnco Announce Joint Investor Breakfast in Chicago to Discuss Immuno-Oncology Developments - Nasdaq
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving ... - Bluefield Daily Telegraph
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following Positive Data Release | TIL Stock News - GuruFocus
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | - GuruFocus
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in - GlobeNewswire
Instil Bio (TIL) Shares Surge on New Clinical Development Plans - GuruFocus
Instil Bio stock rises on cancer trial updates (TIL:NASDAQ) - Seeking Alpha
Instil Bio (TIL) Maintains Buy Rating as Price Target is Adjusted | TIL Stock News - GuruFocus
Instil Bio stock price target cut to $105 by H.C. Wainwright - Investing.com Nigeria
Instil Bio (TIL) Price Target Reduced by Analyst | TIL Stock News - GuruFocus
Instil Bio Partners with ImmuneOnco for Cancer Therapy - TipRanks
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | TIL Stock News - GuruFocus
Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn - marketscreener.com
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ... - Bluefield Daily Telegraph
Instil Bio's Lung Cancer Drug Achieves 23% Response Rate in Phase 2 Trial, Major Results Expected in Late 2025 - Stock Titan
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
(TIL) Investment Analysis - news.stocktradersdaily.com
Instil (TIL) Projects Financial Stability Through 2026 | TIL Sto - GuruFocus
Instil Bio, Inc. SEC 10-Q Report - TradingView
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Instil Bio Inc expected to post a loss of $2.59 a shareEarnings Preview - TradingView
Trading (TIL) With Integrated Risk Controls - news.stocktradersdaily.com
Financial Metrics Check: Microbot Medical Inc (MBOT)’s Ratios for Trailing Twelve Months - DWinneX
Investor’s Toolkit: Key Ratios for Assessing Instil Bio Inc (TIL)’s Performance - DWinneX
TIL’s Stock Market Adventure: -33.05% YTD Growth Amidst Volatility - investchronicle.com
Have you been able to find a good deal on Instil Bio Inc’s shares? - uspostnews.com
Instil Bio Inc (TIL) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
(TIL) Trading Report - news.stocktradersdaily.com
Here's Why Summit Therapeutics Stock Soared 15% on Friday - Nasdaq
GT’s Debt-to-Equity Ratio at 1.85: What It Means for Goodyear Tire & Rubber Co’s Future - investchronicle.com
Where are the Opportunities in (TIL) - news.stocktradersdaily.com
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally - GlobeNewswire Inc.
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market - GlobeNewswire
SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
The Significance of Moving Averages in New Found Gold Corp Inc. (NFGC) Price Performance - investchronicle.com
Instil Bio Inc Stock (TIL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):